Transform the future of cancer screening
MCED tests like the Cancerguard test can help detect hard-to-find cancers and in earlier stages when they are more treatable. Designed for adults aged 50–84 with no history of cancer in the past three years, it aims to detect deadly, hard-to-find cancers (e.g., pancreatic, liver, ovarian) early, though it is not a replacement for standard screenings. Cancerguard showed a 68% sensitivity for the most deadly cancers with the lowest 5-year survival rates like pancreatic, lung, liver, esophageal, stomach, and ovarian cancers and 64% sensitivity in the intended population. It can offer clear, life-changing insights earlier, when treatment can make the biggest difference.* ** Availability outside the United States may vary by region. *Cancerguard Clinician Brochure. Exact Sciences Corporation. Madison, WI. **Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10-45.
Products/Services That Might Help In Your Journey
Personalized Genomic Insights For Patients With Early-Stage Breast Cancer
Personalized genomic insights for early-stage HR+, HER2- breast cancer
Microbiome Test
GutID’s high-resolution, high-accuracy data reveals the full gut microbiome
Non-Invasive CRC Screening
A noninvasive and effective prescription-based colon cancer screening test
Non-Invasive Cancer Detection
A novel diagnostic modality based on single cell biophysical markers